Search company, investor...

U3 Pharma


Dead | Dead

Total Raised


About U3 Pharma

U3 Pharma is involved in targeted cancer drug development. The Company is advancing a portfolio of novel antibody-based therapeutics that will be used as mono therapies and combination therapies for the treatment of cancer. The two lead antibodies are nearing the clinic as potential therapies for breast, lung and colorectal cancers, among others.

Headquarters Location



Missing: U3 Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: U3 Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing U3 Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

U3 Pharma is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

U3 Pharma Patents

U3 Pharma has filed 24 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Medical ethics
  • MicroRNA
patents chart

Application Date

Grant Date


Related Topics




Experimental cancer drugs, Monoclonal antibodies, Clusters of differentiation, Antineoplastic drugs, Monoclonal antibodies for tumors


Application Date


Grant Date



Related Topics

Experimental cancer drugs, Monoclonal antibodies, Clusters of differentiation, Antineoplastic drugs, Monoclonal antibodies for tumors



Latest U3 Pharma News

U3 Pharma Raises Euro 13.25 (US$14.75) Million in a Second Round Financing.. -- re> MARTINSRIED, Germany, Sept. 15 /PRNewswire/ --

Jul 9, 2013

U3 Pharma Raises Euro 13.25 (US$14.75) Million in a Second Round Financing... -- re> MARTINSRIED, Germany, Sept. 15 /PRNewswire/ -- U3 Pharma Raises Euro 13.25 (US$14.75) Million in a Second Round Financing Led By Atlas Venture and LCF Rothschild Venture Partners Atlas Venture's Joel Besse and LCF Rothschild's Michele Ollier Join Axel Ullrich, Jean Deleage and Karsten Henco on Supervisory Board MARTINSRIED, Germany, Sept. 15 /PRNewswire/ -- U3 Pharma AG announced today the closing of a euro 13.25 (US$14.75) million second round financing co-led by Atlas Venture (London) and LCF Rothschild Venture Partners (Paris) and including the BioMedical Sciences Investment Fund of Singapore (Singapore). All three are new investors in U3 Pharma. Alta Partners (San Francisco) continued its ongoing support and commitment to the future of the company through a significant investment in this round. Existing investors BioM (Munich) and Medicis Venture Management (Munich) as well as current private investors also participated in the round. In conjunction with the financing, Joel Besse, Atlas Venture and Michele Ollier of LCF Rothschild Venture Partners have joined U3 Pharma's Supervisory Board. "Closing this financing is strong testament to the commitment and faith that the U3 Pharma team has in their company. These attributes, combined with exciting product candidates based on proven and cutting-edge science, attracted Atlas Venture to participate in the financing," stated Joel Besse. "We look forward to supporting the growth of the company, which is a strong representation of the innovative biotechnology continuing to emerge from Germany. " "We feel that U3 Pharma has pulled together a great team that is building a company on solid fundamentals," noted LCF Rothschild Venture Partners' Michele Ollier. "Under the guidance of Mike Rothe, U3 Pharma's Chief Scientific Officer, the company's broadly applicable science and technology platform is generating both antibody and small molecule drugs and is therefore poised to capitalize on two product areas which are revolutionizing the way that cancer and other diseases are treated. " The proceeds will be used to advance several anticancer candidate drugs through IND and into clinical development. U3 Pharma is developing therapeutic products based on targeting specific components of cellular transduction systems involved in diseases such as cancer and other hyper-proliferative diseases. In addition, the financing will be used to support U3 Pharma's leading position among the next generation of signal transduction companies by filing and acquiring complementary intellectual property, performing continued business development activities and engaging in general corporate expansion. "We are delighted to have supported U3 Pharma since its inception and particularly helping to guide the company through the current difficult financing environment," said Jean Deleage of Alta Partners. "The successful closing of this new round in which additional new institutional investors have been brought into the company is a testament to the outstanding progress shown by U3 Pharma in its innovative science and corporate development. " "This financing brings considerable complementary international expertise and reach from our new investors. This combined with the solid foundations already in place will allow U3 Pharma to rapidly advance our product development programs," said Ed Stuart, Chief Business Officer of U3 Pharma. U3 Pharma is advancing several antibody and small molecule product candidates towards clinical development based on disrupting specific signal transduction pathways. These pathways are one of the most important mechanisms through which cells communicate processes such as proliferation, growth, metabolic regulation and survival. U3 Pharma is collaborating with Abgenix for therapeutic antibodies and EvotecOAI for the discovery and development of small molecule drugs. "The completion of this financing round is very exciting as we are in the position whereby we can capitalize on the advances that have been made in the translation of premier science into products that will benefit patients and address the significant unmet medical need associated with cancer," commented Prof. Axel Ullrich, founder of U3 Pharma and Director, Max Planck Institute for Biochemistry. About U3 Pharma U3 Pharma AG is a biopharmaceutical company focused on the creation of novel therapeutic products that specifically target key components of cellular signal transduction systems that are involved in major important human diseases such as cancer. The company has licensed a portfolio of validated drug targets from the Max Planck Society based on pioneering research by Prof. Axel Ullrich. These drug targets have been used to discover a portfolio of therapeutic antibodies and small molecules candidates. In addition, U3 Pharma has created a second-generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. U3 Pharma is privately held and based in Martinsried, Munich, Germany. For additional information, please visit SOURCE U3 Pharma AG

U3 Pharma Frequently Asked Questions (FAQ)

  • Where is U3 Pharma's headquarters?

    U3 Pharma's headquarters is located at Martinsried.

  • What is U3 Pharma's latest funding round?

    U3 Pharma's latest funding round is Dead.

  • How much did U3 Pharma raise?

    U3 Pharma raised a total of $55.15M.

  • Who are the investors of U3 Pharma?

    Investors of U3 Pharma include Daiichi Sankyo, Alta Partners, Edmond de Rothschild, Atlas Venture, EQT Life Sciences and 6 more.

  • Who are U3 Pharma's competitors?

    Competitors of U3 Pharma include Kiadis Pharma, OncoMed Pharmaceuticals, Crown Bioscience, GANYMED Pharmaceuticals, Activate Immunotherapy, Syndax Pharmaceuticals, Alligator Bioscience, Tolera Therapeutics, MabVax Therapeutics, GlobeImmune and 20 more.

Compare U3 Pharma to Competitors


Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

PNP Therapeutics

PNP Therapeutics is dedicated to the development and commercialization of a cancer treatment approach that is predicated on well-documented evidence that solid tumors can be compelled to develop their own chemotherapy and thus elicit their own self-destruction.


Proacta is a clinical-stage, biopharmaceutical company focused on addressing unmet needs in the field of cancer with current efforts directed towards the development of hypoxia-activated prodrugs that target treatment-resistant cancer cells.

Antisense Pharma

Antisense Pharma is a biopharmaceutical company committed to researching, developing and marketing drugs that enable targeted treatment of aggressive tumor diseases. The company's main objective is to extend the life expectancy of patients considerably and, at the same time, improve quality of life.

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.